Molleman A - Search Results

1

Cannabinoid signalling.

Demuth DG, Molleman A. Demuth DG, et al. Among authors: molleman a. Life Sci. 2006 Jan 2;78(6):549-63. doi: 10.1016/j.lfs.2005.05.055. Epub 2005 Aug 18. Life Sci. 2006. PMID: 16109430 Review.

2

Modulation of the release of endogenous adenosine by cannabinoids in the myenteric plexus-longitudinal muscle preparation of the guinea-pig ileum.

Begg M, Dale N, Llaudet E, Molleman A, Parsons ME. Begg M, et al. Among authors: molleman a. Br J Pharmacol. 2002 Dec;137(8):1298-304. doi: 10.1038/sj.bjp.0704985. Br J Pharmacol. 2002. PMID: 12466239 Free PMC article.

3

Signal transduction of cannabinoid CB1 receptors in a smooth muscle cell line.

Begg M, Baydoun A, Parsons ME, Molleman A. Begg M, et al. Among authors: molleman a. J Physiol. 2001 Feb 15;531(Pt 1):95-104. doi: 10.1111/j.1469-7793.2001.0095j.x. J Physiol. 2001. PMID: 11179394 Free PMC article.

4

Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain.

Thiemann G, Watt CA, Ledent C, Molleman A, Hasenöhrl RU. Thiemann G, et al. Among authors: molleman a. Behav Brain Res. 2009 Jun 8;200(1):60-7. doi: 10.1016/j.bbr.2008.12.035. Epub 2009 Jan 8. Behav Brain Res. 2009. PMID: 19162082

5

The CB(1) cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus.

Thiemann G, Di Marzo V, Molleman A, Hasenöhrl RU. Thiemann G, et al. Among authors: molleman a. Pharmacol Biochem Behav. 2008 May;89(3):384-91. doi: 10.1016/j.pbb.2008.01.010. Epub 2008 Jan 26. Pharmacol Biochem Behav. 2008. PMID: 18294680

6

The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization.

Thiemann G, van der Stelt M, Petrosino S, Molleman A, Di Marzo V, Hasenöhrl RU. Thiemann G, et al. Among authors: molleman a. Behav Brain Res. 2008 Mar 5;187(2):289-96. doi: 10.1016/j.bbr.2007.09.022. Epub 2007 Sep 25. Behav Brain Res. 2008. PMID: 17988751

7

The genetic versus pharmacological invalidation of the cannabinoid CB(1) receptor results in differential effects on 'non-associative' memory and forebrain monoamine concentrations in mice.

Thiemann G, Fletcher BC, Ledent C, Molleman A, Hasenöhrl RU. Thiemann G, et al. Among authors: molleman a. Neurobiol Learn Mem. 2007 Nov;88(4):416-23. doi: 10.1016/j.nlm.2007.07.013. Epub 2007 Sep 19. Neurobiol Learn Mem. 2007. PMID: 17884611

8

Cannabinoid signalling in TNF-alpha induced IL-8 release.

Mormina ME, Thakur S, Molleman A, Whelan CJ, Baydoun AR. Mormina ME, et al. Among authors: molleman a. Eur J Pharmacol. 2006 Jul 1;540(1-3):183-90. doi: 10.1016/j.ejphar.2006.04.015. Epub 2006 May 5. Eur J Pharmacol. 2006. PMID: 16714014

9

Arachidonic acid mediates non-capacitative calcium entry evoked by CB1-cannabinoid receptor activation in DDT1 MF-2 smooth muscle cells.

Demuth DG, Gkoumassi E, Dröge MJ, Dekkers BG, Esselink HJ, van Ree RM, Parsons ME, Zaagsma J, Molleman A, Nelemans SA. Demuth DG, et al. Among authors: molleman a. J Cell Physiol. 2005 Oct;205(1):58-67. doi: 10.1002/jcp.20390. J Cell Physiol. 2005. PMID: 15887237

10

Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells.

Ihenetu K, Molleman A, Parsons M, Whelan C. Ihenetu K, et al. Among authors: molleman a. Eur J Pharmacol. 2003 Mar 19;464(2-3):207-15. doi: 10.1016/s0014-2999(03)01379-7. Eur J Pharmacol. 2003. PMID: 12620515

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results